Organon & Co.
Clinical trials sponsored by Organon & Co., explained in plain language.
A global healthcare company focused on women's health and biosimilars.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cream could help kids with psoriasis Results expected Oct 2026 (estimated)
- New cream could soothe eczema in babies as young as 3 months Results expected Aug 2027 (estimated)
-
New hormonal IUD shows promise in early birth control trial
Disease control CompletedThis phase 2 trial tested three different doses of a new hormonal intrauterine system (IUS) releasing etonogestrel against a standard copper IUD for contraception. 84 healthy women who had given birth took part to see how safe and acceptable the devices were, and how they affecte…
Phase 2 • Sponsor: Organon and Co • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Birth control implant may last 5 years, study shows
Disease control CompletedThis study looked at whether the etonogestrel implant (Nexplanon), currently approved for 3 years of use, remains effective for up to 5 years. About 500 women aged 35 or younger who already had the implant for 3 years took part. Researchers tracked pregnancy rates and side effect…
Phase 3 • Sponsor: Organon and Co • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Cholesterol combo pill shows promise for High-Risk hearts
Disease control CompletedThis study tested whether adding ezetimibe to atorvastatin (a common cholesterol drug) works better than atorvastatin alone in people at very high risk for heart attacks or strokes. Researchers enrolled 137 adults with atherosclerotic cardiovascular disease and measured how much …
Phase 4 • Sponsor: Organon and Co • Aim: Disease control
Last updated Jun 26, 2026 15:09 UTC
-
New eczema cream shows promise in large trial
Disease control CompletedThis study tested a cream called tapinarof in 406 people aged 2 and older with moderate to severe eczema. Participants applied the cream or a placebo once daily for 8 weeks. The main goal was to see if the cream could make skin clear or almost clear. Results are being analyzed to…
Phase 3 • Sponsor: Organon and Co • Aim: Disease control
Last updated Jun 26, 2026 12:47 UTC
-
New pill could ease severe endometriosis pain
Symptom relief CompletedThis study tested a new medication called OG-6219 in 354 women aged 18 to 49 with moderate to severe endometriosis-related pain. The goal was to see if three different doses could safely reduce pelvic pain compared to a placebo. The trial is complete, and results will show how we…
Phase 2 • Sponsor: Organon and Co • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
New cream shows promise for kids with severe eczema
Symptom relief CompletedThis study tested a cream called tapinarof in 36 children aged 2 to 17 with severe eczema covering large areas of skin. The goal was to see how much of the drug gets into the body and whether it is safe. Children applied the cream once daily, and researchers monitored side effect…
Phase 2 • Sponsor: Organon and Co • Aim: Symptom relief
Last updated Jun 26, 2026 13:50 UTC
-
New eczema cream shows promise in major trial
Symptom relief CompletedThis study tested a cream called tapinarof on 407 people aged 2 and older with moderate to severe eczema (atopic dermatitis). Participants applied the cream or a placebo once daily for 8 weeks. The goal was to see if the cream could clear or nearly clear the skin rash better than…
Phase 3 • Sponsor: Organon and Co • Aim: Symptom relief
Last updated Jun 26, 2026 13:45 UTC